Sinus bradycardia associated with daclizumab in liver transplant recipients: Report of 3 cases

Adel Bassily-Marcus; Roopa Kohli-Seth; Andrew Leibowitz; Victor Murgolo; John Oropello; Anthony Manasia; Ernest Benjamin

Sinus bradycardia associated with daclizumab in liver transplant recipients: Report of 3 cases

Adel Bassily-Marcus, Roopa Kohli-Seth, Andrew Leibowitz, Victor Murgolo, John Oropello, Anthony Manasia, Ernest Benjamin

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Daclizumab is a commonly used immunosuppressive agent for prophylaxis of solid organ rejection. Although rare, the cardiovascular adverse effects of daclizumab include sinus tachycardia, hypotension, and hypertension. Here, we report 3 patients who developed significant and prolonged sinus bradycardia after receiving daclizumab following orthotopic liver transplant. Daclizumab should be considered a possible cause of bradycardia following its administration in orthotopic liver transplant.

Original language	English
Pages (from-to)	80-83
Number of pages	4
Journal	Experimental and Clinical Transplantation
Volume	6
Issue number	1
State	Published - Mar 2008

Keywords

Bradyarrhythmias
Drud-induced
Famotidine
Tranplantation
Zenapax

Cite this

@article{47e21945d3af4d5c997871f40529e527,

title = "Sinus bradycardia associated with daclizumab in liver transplant recipients: Report of 3 cases",

abstract = "Daclizumab is a commonly used immunosuppressive agent for prophylaxis of solid organ rejection. Although rare, the cardiovascular adverse effects of daclizumab include sinus tachycardia, hypotension, and hypertension. Here, we report 3 patients who developed significant and prolonged sinus bradycardia after receiving daclizumab following orthotopic liver transplant. Daclizumab should be considered a possible cause of bradycardia following its administration in orthotopic liver transplant.",

keywords = "Bradyarrhythmias, Drud-induced, Famotidine, Tranplantation, Zenapax",

author = "Adel Bassily-Marcus and Roopa Kohli-Seth and Andrew Leibowitz and Victor Murgolo and John Oropello and Anthony Manasia and Ernest Benjamin",

year = "2008",

month = mar,

language = "English",

volume = "6",

pages = "80--83",

journal = "Experimental and Clinical Transplantation",

issn = "1304-0855",

publisher = "Baskent University",

number = "1",

}

TY - JOUR

T1 - Sinus bradycardia associated with daclizumab in liver transplant recipients

T2 - Report of 3 cases

AU - Bassily-Marcus, Adel

AU - Kohli-Seth, Roopa

AU - Leibowitz, Andrew

AU - Murgolo, Victor

AU - Oropello, John

AU - Manasia, Anthony

AU - Benjamin, Ernest

PY - 2008/3

Y1 - 2008/3

N2 - Daclizumab is a commonly used immunosuppressive agent for prophylaxis of solid organ rejection. Although rare, the cardiovascular adverse effects of daclizumab include sinus tachycardia, hypotension, and hypertension. Here, we report 3 patients who developed significant and prolonged sinus bradycardia after receiving daclizumab following orthotopic liver transplant. Daclizumab should be considered a possible cause of bradycardia following its administration in orthotopic liver transplant.

AB - Daclizumab is a commonly used immunosuppressive agent for prophylaxis of solid organ rejection. Although rare, the cardiovascular adverse effects of daclizumab include sinus tachycardia, hypotension, and hypertension. Here, we report 3 patients who developed significant and prolonged sinus bradycardia after receiving daclizumab following orthotopic liver transplant. Daclizumab should be considered a possible cause of bradycardia following its administration in orthotopic liver transplant.

KW - Bradyarrhythmias

KW - Drud-induced

KW - Famotidine

KW - Tranplantation

KW - Zenapax

UR - http://www.scopus.com/inward/record.url?scp=46049114134&partnerID=8YFLogxK

M3 - Article

C2 - 18405250

AN - SCOPUS:46049114134

SN - 1304-0855

VL - 6

SP - 80

EP - 83

JO - Experimental and Clinical Transplantation

JF - Experimental and Clinical Transplantation

IS - 1

ER -

Sinus bradycardia associated with daclizumab in liver transplant recipients: Report of 3 cases

Abstract

Keywords

Fingerprint

Cite this